Compare PRTA & FWRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | FWRD |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.7M | 482.3M |
| IPO Year | 2013 | 2024 |
| Metric | PRTA | FWRD |
|---|---|---|
| Price | $8.41 | $14.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $19.00 | ★ $37.50 |
| AVG Volume (30 Days) | 534.3K | ★ 726.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.54 |
| EPS | ★ 0.60 | N/A |
| Revenue | $814,000.00 | ★ $1,269,573,000.00 |
| Revenue This Year | $1,111.38 | $6.57 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.61 | $7.86 |
| 52 Week High | $11.80 | $32.00 |
| Indicator | PRTA | FWRD |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 54.47 |
| Support Level | $8.12 | $11.75 |
| Resistance Level | $10.29 | $14.73 |
| Average True Range (ATR) | 0.43 | 0.97 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 27.79 | 51.23 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.